journal article·2016-01-02Open access

Fullerene C60 functionalized γ-Fe2O3 magnetic nanoparticle: Synthesis, characterization, and biomedical applications

Ersin Kılınç

Abstract

Hybrid magnetic nanoparticles composed from C60 fullerene and γ-Fe2O3 were synthesized by hydrothermal method. XRD, FT-IR, VSM, SEM, and HR-TEM were employed for characterizations. The magnetic saturation value of C60-γ-Fe2O3 magnetic nanoparticles was 66.5 emu g(-1). Concentration of Fe in nanoparticles as determined by ICP-OES was 40.7% Fe. Particle size of C60-γ-Fe2O3 magnetic nanoparticles was smaller than 10 nm. Maximum adsorption capacity of C60-γ-Fe2O3 for flurbiprofen, a non-steroidal anti-inflammatory drug, was calculated from Langmuir isotherm as 142.9 mg g(-1).
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Fullerene Chemistry and Applications · Graphene research and applications · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Laboratory Techniques, Vocational School of Healthcare Studies, Mardin Artuklu University, Mardin, Turkey

References (42)

Show source-provided references
1. 10.1016/j.molcatb.2006.02.00410.1016/j.molcatb.2006.02.004 ↗
2. 10.1093/toxsci/kfm24310.1093/toxsci/kfm243 ↗
3. Barszcz B · Acta Phys Pol A · 2007 · 112 · 14310.12693/APhysPolA.112.S-143 ↗
4. 10.1088/0022-3727/36/13/20310.1088/0022-3727/36/13/203 ↗
5. 10.1002/(SICI)1521-3773(20000515)39:10<1845::AID-ANIE1845>3.0.CO;2-Q10.1002/(SICI)1521-3773(20000515)39:10<1845::AID-ANIE1845>3.0.CO;2-Q ↗
6. 10.1158/1078-0432.CCR-06-051410.1158/1078-0432.CCR-06-0514 ↗
7. 10.1016/j.msec.2007.06.00410.1016/j.msec.2007.06.004 ↗
8. 10.1016/j.tet.2008.10.06610.1016/j.tet.2008.10.066 ↗
9. Ganachari SV · Int J Sci Res · 2012 · 1 · 77
10. 10.1021/ar900002610.1021/ar9000026 ↗
11. 10.1109/TNB.2003.82027710.1109/TNB.2003.820277 ↗
12. 10.1023/A:101102013214010.1023/A:1011020132140 ↗
13. 10.1016/j.biomaterials.2011.01.03210.1016/j.biomaterials.2011.01.032 ↗
14. 10.1021/mp050068r10.1021/mp050068r ↗
15. 10.1021/ar200027710.1021/ar2000277 ↗
16. 10.1556/JPC.22.2009.5.610.1556/JPC.22.2009.5.6 ↗
17. 10.1080/00032719.2012.69622410.1080/00032719.2012.696224 ↗
18. 10.1038/318162a010.1038/318162a0 ↗
19. 10.1016/j.molcatb.2003.05.00410.1016/j.molcatb.2003.05.004 ↗
20. 10.1016/j.jmmm.2003.07.00610.1016/j.jmmm.2003.07.006 ↗
21. 10.1016/j.msec.2012.05.04810.1016/j.msec.2012.05.048 ↗
22. 10.1088/0953-8984/9/25/01310.1088/0953-8984/9/25/013 ↗
23. 10.1023/A:101155671447310.1023/A:1011556714473 ↗
24. 10.1016/j.freeradbiomed.2007.05.00510.1016/j.freeradbiomed.2007.05.005 ↗
25. 10.1002/1521-3773(20001201)39:23<4254::AID-ANIE4254>3.0.CO;2-O10.1002/1521-3773(20001201)39:23<4254::AID-ANIE4254>3.0.CO;2-O ↗
26. 10.1016/j.molcatb.2012.08.01010.1016/j.molcatb.2012.08.010 ↗
27. Oh W · J Ind Eng Chem · 2007 · 13 · 1208
28. 10.1021/nn800422k10.1021/nn800422k ↗
29. 10.2217/nnm.09.1110.2217/nnm.09.11 ↗
30. 10.1039/b920853d10.1039/b920853d ↗
31. 10.1016/S0142-9612(02)00080-710.1016/S0142-9612(02)00080-7 ↗
32. 10.1016/S0925-4005(01)00948-010.1016/S0925-4005(01)00948-0 ↗
33. 10.3390/molecules1704385810.3390/molecules17043858 ↗
34. 10.1254/jphs.CPJ06002X10.1254/jphs.CPJ06002X ↗
35. 10.1021/cm011535+10.1021/cm011535+ ↗
36. 10.1016/S0090-6980(98)00018-510.1016/S0090-6980(98)00018-5 ↗
37. 10.3390/s9040297610.3390/s90402976 ↗
38. 10.1021/ja044688h10.1021/ja044688h ↗
39. 10.1016/j.addr.2009.11.00210.1016/j.addr.2009.11.002 ↗
40. 10.1007/s11095-012-0679-710.1007/s11095-012-0679-7 ↗
41. 10.1002/jctb.373510.1002/jctb.3735 ↗
42. 10.1016/j.toxlet.2009.08.01710.1016/j.toxlet.2009.08.017 ↗